Efficacy and Tolerability of Controlled-Release Paroxetine
By Robert N. Golden, MD
Efficacy of Combined Pharmacological and Cognitive- Behavioral Treatments For Anxiety Disorders
By Steven E. Bruce, PhD and Kamila S. White, PhD
COMPLICATED CASE HISTORIES
Efficacy of High-Dose Aripiprazole for Treatment-Resistant Schizoaffective Disorder: A Case Report
By Omer Saatcioglu, Sevda Gumus, Kirkor Kamberyan, Medaim Yanik
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder
By Christoph U. Correll, Richard C. Josiassen, Grace S. Liang, Joshua Burke, Christopher F. O’Brien
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder
By John M. Kane, Christoph U. Correll, Grace S. Liang, Joshua Burke, Christopher F. O’Brien
El libro negro de dosificación y monitoreo de sustancias psicotrópicas
Dr. C. DeBattista, Dr. A.F. Schatzberg Comentario por Dr. A. Monchablon Espinoza
Enfoque clínico
Apatía y depresión después de un accidente cerebrovascular
Dr. Sergio E. Starkstein y Dr. Facundo Manes
Avances en la farmacoterapia del trastorno por estrés postraumático
Dr. Charles R. Marmar, Dr. Thomas C. Neylan y Dr. Frank B. Schoenfeld